Atomo Diagnostics Ltd (ASX: AT1) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Atomo Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.98 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 639.20 million
Earnings per share -0.012
Dividend per share N/A
Year To Date Return 13.64%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Atomo Diagnostics Ltd (ASX: AT1)
    Latest News

    Doctor doing a telemedicine using laptop at a medical clinic
    Share Gainers

    Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

    Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

    Read more »

    Two happy scientists analysing test results.
    Share Gainers

    Guess which ASX pharmaceutical stock just rocketed 122%!

    Investors are piling into the ASX pharmaceutical stock on Wednesday.

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    3 ASX healthcare shares rocketing 20% to 100% today

    These ASX shares are thumping the market on Tuesday and making their shareholders smile.

    Read more »

    laboratory workers looking disappointed
    Earnings Results

    3 ASX healthcare shares punished following full-year results

    It wasn't so rosy for all those reporting earnings today

    Read more »

    a woman winces as she inserts a home diagnostic test for COVID-19 up her nose with her sofa in the background.
    Earnings Results

    Negative result: Atomo Diagnostics (ASX: AT1) shares plunge 18% on half-year earnings

    What did the diagnostics report in its results?

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Coronavirus News

    Why are ASX COVID test shares climbing today?

    COVID-19 tests are in focus again today.

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Healthcare Shares

    Here's why the Atomo (ASX:AT1) share price is rocketing 17% today

    Atomo is cementing its presence across key markets.

    Read more »

    female nurse in scrubs
    Healthcare Shares

    Why has the Atomo Diagnostics (ASX: AT1) share price surged 50% since Christmas?

    Could this be why the company's stock has taken off lately?

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    Why is the Atomo Diagnostics (ASX:AT1) share price wobbling on Thursday?

    It's been a busy week so far for the medical devices company

    Read more »

    Woman prepares to insert a swab in her nose to test for COVID-19 at home.
    Healthcare Shares

    Is AM Diagnostics listed on the ASX?

    The supplier of Australia's only approved at-home COVID-19 tests is the talk of the ASX today.

    Read more »

    share price dropping
    Share Fallers

    Why Afterpay, Atomo, Opthea, & Sealink shares are falling today

    These ASX shares are in the red on Tuesday...

    Read more »

    ASX shares downgrade A young woman with tattoos puts both thumbs down and scrunches her face with the bad news.
    Share Market News

    Here's why the Atomo (ASX:AT1) share price is crashing 9% today

    This ASX share is having a bad start to the week...

    Read more »

    AT1 ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Atomo Diagnostics Ltd

    Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions

    AT1 Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Jul 2024 $0.03 $0.00 0.00% 283,244 $0.03 $0.03 $0.03
    18 Jul 2024 $0.03 $0.00 0.00% 539 $0.03 $0.03 $0.03
    17 Jul 2024 $0.03 $0.00 0.00% 43,742 $0.03 $0.03 $0.03
    16 Jul 2024 $0.03 $0.00 0.00% 7,705 $0.03 $0.03 $0.03
    15 Jul 2024 $0.03 $0.00 0.00% 358,114 $0.03 $0.03 $0.03
    12 Jul 2024 $0.03 $0.00 0.00% 140,127 $0.03 $0.03 $0.03
    11 Jul 2024 $0.03 $0.00 0.00% 934,066 $0.03 $0.03 $0.03
    10 Jul 2024 $0.03 $0.00 0.00% 76,456 $0.03 $0.03 $0.03
    09 Jul 2024 $0.03 $0.00 0.00% 676,100 $0.03 $0.03 $0.03
    08 Jul 2024 $0.03 $0.00 0.00% 408,769 $0.03 $0.03 $0.03
    05 Jul 2024 $0.03 $0.00 0.00% 366,495 $0.03 $0.03 $0.03
    04 Jul 2024 $0.02 $0.00 0.00% 13,093 $0.03 $0.03 $0.02
    03 Jul 2024 $0.02 $0.00 0.00% 20,754 $0.02 $0.02 $0.02
    02 Jul 2024 $0.02 $0.00 0.00% 468,308 $0.03 $0.03 $0.02
    01 Jul 2024 $0.03 $0.00 0.00% 12,831 $0.03 $0.03 $0.03
    28 Jun 2024 $0.03 $0.00 0.00% 604,498 $0.03 $0.03 $0.03
    27 Jun 2024 $0.03 $0.00 0.00% 244,470 $0.03 $0.03 $0.03
    26 Jun 2024 $0.03 $0.00 0.00% 713,272 $0.03 $0.03 $0.03
    25 Jun 2024 $0.03 $0.00 0.00% 814,123 $0.03 $0.03 $0.03
    24 Jun 2024 $0.03 $0.00 0.00% 365,949 $0.03 $0.03 $0.03
    21 Jun 2024 $0.03 $0.00 0.00% 217,620 $0.03 $0.03 $0.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Aug 2023 John Kelly Expiry 666,666 $19,999
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Paul Alexander Kasian Non-Executive Director
    Dr Kasian is an executive director with demonstrated achievement in both domestic and international companies encompassing senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. He is also Chair of Risk Committee.
    Mr John Perry Keith Non-Executive ChairmanNon-Executive Director Dec 2011
    Mr Keith is one of the Managing Directors at BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign, and institutional clients across all areas of investment and institutional banking. He is Member of the Risk Committee.
    Mr John Michael Kelly FounderChief Executive OfficerManaging Director Apr 2010
    Mr Kelly has focused on developing and commercializing innovative healthcare products that enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of the Mirage Swift and Activa mask systems.
    Ms Deborah Neff Non-Executive Director Sep 2021
    Ms Neff has spent most of her career building global businesses. As principal of DJN Consulting, LLC based in the San Francisco Bay Area, Deborah currently works with several privately held healthcare start-up companies providing strategic business advice and mentoring to the executive management teams. Previously was CEO of Evanostics, LLC, Pathwork Diagnostics Inc, and COO at Complete Genomics following a 15-year career with Becton Dickinson, where she last served as President of BD Biosciences, a global business unit of the company. She is an Executive Trustee of the University of California, Davis Foundation and chairs the College of Biological Sciences Leadership Council at the University. He is also member of the Risk Committee.
    Dr Cheri Louise Walker Non-Executive Director Nov 2022
    Dr Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher.
    Mr Mathew Leslie Watkins Company Secretary Jun 2024
    William Souter Chief Financial Officer
    Chandra Sukumar Chief Operating Officer
    Mathew Leslie Watkins Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    GZ Family Holdings Pty Ltd 79,787,536 13.98%
    Dalraida Holdings Pty Limited 65,120,000 11.41%
    Global Health Investment Fund 64,811,280 11.35%
    Mr Xiaoyi Lin 11,500,000 2.01%
    Grand Challenges Canada 11,390,824 2.00%
    Liverbird Pty Ltd 10,931,653 1.91%
    ID&E Pty Ltd 9,032,248 1.58%
    Australia North Holdings Pty 8,100,000 1.42%
    Mark Andrew Smith 7,790,224 1.36%
    Mr Ian Fredrick Johnson 7,506,080 1.31%
    John Michael Kelly 7,370,248 1.29%
    Leo James Lynch 7,321,121 1.28%
    Ruth Karen Devney 5,626,408 0.99%
    Australia West Holdings Pty Ltd 5,250,000 0.92%
    Sokolov Pty Ltd 4,031,888 0.71%
    Rue Des Rocs Pty Ltd 3,800,000 0.67%
    H & L Management Pty Ltd 3,700,000 0.65%
    Citicorp Nominees Pty Limited 3,684,031 0.65%
    BNP PARIBAS NOMINEES PTY LTD 3,399,373 0.60%
    Miss Lisa Marie Mackenzie 3,351,968 0.59%